Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance

The Phase 3b BE RADIANT study met its primary endpoint and all ranked secondary endpoints Bimekizumab demonstrated superiority to Cosentyx® (secukinumab) for PASI 100 at week 16 and PASI 100 at week 48, with no new safety signals observed for bimeki... Biopharmaceuticals, Dermatology UCB, bimekizumab, plaque psoriasis, psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news